Sauchelli S. Digitalising diabetes support groups in response to the coronavirus COVID ‐19 outbreak: a collaborative initiative. Pract Diabetes. 2020 Nov;37(6):208. doi: 10.1002/pdi.2306
Sauchelli S. Digitalising diabetes support groups in response to the coronavirus COVID-19 outbreak: a collaborative initiative. Pract Diabetes. 2020 Nov;37(6):208-210a. doi: 10.1002/pdi.2306
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Croft DE, van Hemert J, Wykoff CC, Clifton D, Verhoek M, Fleming A, Brown DM. Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Osli Retina. 2014 Jul 1;45(4):312-7. doi: 10.3928/23258160-20140709-07
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.